BioXcel Therapeutics, Inc.
BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new tā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.80
Price+0.66%
$0.00
1Y
Price
Market Cap
$24.819m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-4094.7%
EBITDA Margin-6160.7%
Net Profit Margin-5732.5%
Free Cash Flow Margin-4094.7%
EBITDA Margin-6160.7%
Net Profit Margin-5732.5%
Free Cash Flow MarginRevenue
$680k
+5.9%
1y CAGR-0.5%
3y CAGR+66.6%
5y CAGREarnings
-$75.334m
-7.8%
1y CAGR+13.9%
3y CAGR+8.4%
5y CAGREPS
-$6.70
-16.9%
1y CAGR+44.9%
3y CAGR+32.7%
5y CAGRBook Value
-$105.543m
$34.025m
Assets$139.568m
Liabilities$100.289m
DebtDebt to Assets
294.8%
-1.7x
Debt to EBITDAFree Cash Flow
-$57.381m
+0.4%
1y CAGR+24.7%
3y CAGR+14.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company